Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jardiance's CV Benefit: Can A Single Study Carry The Day At FDA?

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency finds support for cardiovascular mortality benefit with Boehringer/Lilly's diabetes drug, but advisory committee will review weaknesses in outcomes trial's component data.


Related Content

Victoza’s Non-Cardio Safety May Dominate At FDA Panel Review
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts